{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+Mirabegron", "query": { "intervention": "Placebo for Mirabegron" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 30, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+Mirabegron&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-18T09:06:00.022Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00662909", "title": "A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urinary Bladder, Overactive" ], "interventions": [ { "name": "Mirabegron", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2149, "start_date": "2008-03-28", "completion_date": "2009-04-22", "has_results": true, "last_update_posted_date": "2024-11-20", "last_synced_at": "2026-09-18T09:06:00.022Z", "location_count": 109, "location_summary": "Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 100 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00662909" }, { "nct_id": "NCT05990387", "title": "MIrabegron and Physiological Function in Cold Environments", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Resting Energy Expenditure", "Thermogenesis", "Brown Adipose Tissue" ], "interventions": [ { "name": "Mirabegron", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 17, "start_date": "2023-07-19", "completion_date": "2024-04-23", "has_results": true, "last_update_posted_date": "2025-07-03", "last_synced_at": "2026-09-18T09:06:00.022Z", "location_count": 1, "location_summary": "Bloomington, Indiana", "locations": [ { "city": "Bloomington", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05990387" }, { "nct_id": "NCT00688688", "title": "Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urinary Bladder, Overactive" ], "interventions": [ { "name": "Mirabegron", "type": "DRUG" }, { "name": "Tolterodine", "type": "DRUG" }, { "name": "Placebo to Mirabegron", "type": "DRUG" }, { "name": "Placebo to Tolterodine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2792, "start_date": "2008-04-25", "completion_date": "2010-05-06", "has_results": true, "last_update_posted_date": "2024-11-20", "last_synced_at": "2026-09-18T09:06:00.022Z", "location_count": 106, "location_summary": "Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 96 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00688688" }, { "nct_id": "NCT03817931", "title": "Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Overactive Bladder", "Dementia", "Lower Urinary Tract Symptoms", "Incontinence, Urge" ], "interventions": [ { "name": "Anticholinergic", "type": "DRUG" }, { "name": "Beta-3 Agonists, Adrenergic", "type": "DRUG" }, { "name": "Functional magnetic resonance imaging (fMRI)", "type": "DIAGNOSTIC_TEST" }, { "name": "Rey Auditory Verbal Learning Test (RAVLT)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Baylor Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "FEMALE", "summary": "18 Years to 90 Years · Female only" }, "enrollment_count": 12, "start_date": "2019-08-05", "completion_date": "2022-02-26", "has_results": false, "last_update_posted_date": "2024-02-02", "last_synced_at": "2026-09-18T09:06:00.022Z", "location_count": 2, "location_summary": "Houston, Texas • Temple, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Temple", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03817931" }, { "nct_id": "NCT01908829", "title": "A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urinary Bladder Diseases", "Urinary Bladder Overactive", "Urologic Diseases" ], "interventions": [ { "name": "mirabegron 25 mg", "type": "DRUG" }, { "name": "mirabegron 50 mg", "type": "DRUG" }, { "name": "solifenacin 5 mg", "type": "DRUG" }, { "name": "solifenacin 10 mg", "type": "DRUG" }, { "name": "mirabegron 25 mg matching placebo", "type": "DRUG" }, { "name": "mirabegron 50 mg matching placebo", "type": "DRUG" }, { "name": "solifenacin 5 mg matching placebo", "type": "DRUG" }, { "name": "solifenacin 10 mg matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Europe Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2174, "start_date": "2013-07-10", "completion_date": "2014-11-25", "has_results": true, "last_update_posted_date": "2024-10-31", "last_synced_at": "2026-09-18T09:06:00.022Z", "location_count": 36, "location_summary": "Tucson, Arizona • Buena Park, California • Los Angeles, California + 31 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Buena Park", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Valley Village", "state": "California" }, { "city": "Brooksville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01908829" }, { "nct_id": "NCT00912964", "title": "A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urinary Bladder, Overactive" ], "interventions": [ { "name": "Mirabegron", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2030, "start_date": "2009-04-28", "completion_date": "2010-04-27", "has_results": true, "last_update_posted_date": "2024-11-21", "last_synced_at": "2026-09-18T09:06:00.022Z", "location_count": 82, "location_summary": "Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 75 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00912964" }, { "nct_id": "NCT02092181", "title": "A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Parkinsons Disease" ], "interventions": [ { "name": "Mirabegron", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daniel Burdick, MD", "sponsor_class": "INDIV", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "30 Years to 85 Years" }, "enrollment_count": 30, "start_date": "2014-03", "completion_date": "2018-07-01", "has_results": true, "last_update_posted_date": "2021-08-16", "last_synced_at": "2026-09-18T09:06:00.022Z", "location_count": 1, "location_summary": "Kirkland, Washington", "locations": [ { "city": "Kirkland", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02092181" }, { "nct_id": "NCT02138747", "title": "A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Overactive Bladder (OAB)" ], "interventions": [ { "name": "Mirabegron", "type": "DRUG" }, { "name": "Tolterodine ER", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 376, "start_date": "2014-07-24", "completion_date": "2015-11-11", "has_results": true, "last_update_posted_date": "2020-02-26", "last_synced_at": "2026-09-18T09:06:00.022Z", "location_count": 22, "location_summary": "Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 19 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Sherman Oaks", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02138747" }, { "nct_id": "NCT02744430", "title": "Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ureteral Obstruction", "Flank Pain" ], "interventions": [ { "name": "Mirabegron", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 33, "start_date": "2017-07-22", "completion_date": "2019-10-31", "has_results": true, "last_update_posted_date": "2022-04-26", "last_synced_at": "2026-09-18T09:06:00.022Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02744430" }, { "nct_id": "NCT02536976", "title": "Mirabegron in Parkinson Disease and Impaired Cognition", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Parkinson Disease", "Overactive Bladder", "Impaired Cognition" ], "interventions": [ { "name": "mirabegron", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HealthPartners Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "25 Years to 80 Years" }, "enrollment_count": 7, "start_date": "2015-12", "completion_date": "2018-08-01", "has_results": true, "last_update_posted_date": "2019-05-08", "last_synced_at": "2026-09-18T09:06:00.022Z", "location_count": 1, "location_summary": "Golden Valley, Minnesota", "locations": [ { "city": "Golden Valley", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02536976" } ] }